ES2193145T3 - Proteinas procoagulants quimericas. - Google Patents

Proteinas procoagulants quimericas.

Info

Publication number
ES2193145T3
ES2193145T3 ES93923220T ES93923220T ES2193145T3 ES 2193145 T3 ES2193145 T3 ES 2193145T3 ES 93923220 T ES93923220 T ES 93923220T ES 93923220 T ES93923220 T ES 93923220T ES 2193145 T3 ES2193145 T3 ES 2193145T3
Authority
ES
Spain
Prior art keywords
proteins
type
factor
procoagulating
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923220T
Other languages
English (en)
Inventor
Debra Pittman
Alnawaz Rehemtulla
John M Wozney
Randal J Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26819212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2193145(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of ES2193145T3 publication Critical patent/ES2193145T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PROPORCIONAN SECUENCIAS NUCLEOTIDAS DE FACTOR VIII PORCINO Y SECUENCIAS HIBRIDAS QUE CODIFICAN PROTEINAS PROCOAGULANTES DE FACTOR DE TIPO VIII QUIMERICO HUMANO/PORCINO. TAMBIEN SE PROPORCIONAN LOS ADN QUE CODIFICAN TALES PROTEINAS PROCOAGULANTES DE FACTOR DE TIPO VIII QUIMERICO, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES PROTEINAS PROCOAGULANTES DE FACTOR DE TIPO VIII QUIMERICO, Y METODOS PARA EL TRATAMIENTO DE HEMOFILIA UTILIZANDO TALES PROTEINAS PROCOAGULANTES DE FACTOR DE TIPO VIII QUIMERICO.
ES93923220T 1992-11-13 1993-10-01 Proteinas procoagulants quimericas. Expired - Lifetime ES2193145T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97608692A 1992-11-13 1992-11-13
US08/121,202 US5563045A (en) 1992-11-13 1993-09-14 Chimeric procoagulant proteins

Publications (1)

Publication Number Publication Date
ES2193145T3 true ES2193145T3 (es) 2003-11-01

Family

ID=26819212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923220T Expired - Lifetime ES2193145T3 (es) 1992-11-13 1993-10-01 Proteinas procoagulants quimericas.

Country Status (9)

Country Link
US (1) US5563045A (es)
EP (2) EP0672138B1 (es)
AT (1) ATE239789T1 (es)
AU (1) AU5298293A (es)
DE (1) DE69332955T2 (es)
DK (1) DK0672138T3 (es)
ES (1) ES2193145T3 (es)
PT (1) PT672138E (es)
WO (1) WO1994011503A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
DE19613620C2 (de) * 1996-04-04 1998-04-16 Steag Micro Tech Gmbh Verfahren und Vorrichtung zum Trocknen von Substraten
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
WO1997040145A1 (en) * 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
EP1144594A1 (en) 1998-11-24 2001-10-17 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
EP1572885A2 (en) * 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
PL2298347T3 (pl) * 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CN102112144A (zh) * 2008-05-16 2011-06-29 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
SI2506868T1 (en) 2009-12-06 2018-04-30 Bioverativ Therapeutics Inc. HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (pt) * 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
HK1214539A1 (zh) 2012-10-30 2016-07-29 Bioverativ Therapeutics Inc. 應用viii因子多肽的方法
EP4122487A1 (en) 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
CN113817069A (zh) 2013-06-28 2021-12-21 比奥贝拉蒂治疗公司 具有xten的凝血酶可裂解连接子和其用途
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
EP3283126B1 (en) 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
BR112018012073A2 (pt) 2015-12-16 2018-11-27 Nz Inst Plant & Food Res Ltd métodos para produzir uma planta com pelo menos um fenótipo associado a nanismo e para identificar uma planta com um genótipo indicativo de pelo menos um fenótipo associado a nanismo, polinucleotídeo isolado, polipeptídeo arf3, construto, célula, planta, parte, propágulo ou progênie de uma planta.
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
JP7672334B2 (ja) * 2018-10-23 2025-05-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法
WO2022032140A2 (en) 2020-08-07 2022-02-10 Amicus Therapeutics, Inc. Vesicle targeting proteins and uses of same
AU2023356318A1 (en) 2022-10-05 2025-05-08 Genxtraits, Inc. Uorf::reporter gene fusions to select sequence changes to gene edit into uorfs to regulate ascorbate genes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII

Also Published As

Publication number Publication date
WO1994011503A3 (en) 1994-07-07
PT672138E (pt) 2003-09-30
EP1308515A3 (en) 2003-05-28
AU5298293A (en) 1994-06-08
EP0672138B1 (en) 2003-05-07
US5563045A (en) 1996-10-08
DE69332955D1 (de) 2003-06-12
DK0672138T3 (da) 2003-08-11
DE69332955T2 (de) 2004-01-29
EP1308515A2 (en) 2003-05-07
EP0672138A1 (en) 1995-09-20
ATE239789T1 (de) 2003-05-15
WO1994011503A2 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
ES2193145T3 (es) Proteinas procoagulants quimericas.
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
ES2105442T3 (es) Analogos de eritropoyetina con sitios adicionales de glicosilacion.
BR9711123A (pt) Quimeras de leucotoxina-gnrh
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DK0612846T3 (da) G-CSF-analogsammensætninger og fremgangsmåder til fremstilling af disse
DE69433690D1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
DE69426121D1 (de) Gen grb3-3, variante und ihre verwendungen
DE69839582D1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
EP0569678A3 (de) Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
PT77238A (de) Substituierte tert.-butanol-derivate verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel
AR013801A1 (es) Nuevas moleculas de acido nucleico aislada, una proteina de epoxido hidrolasa de artropodo hematofago aislada, una formulacion de proteinas deepoxido hidrolasa de pulga, una composicion terapeutica que reduce la infestacion de ectoparasitos hematofagos; uso de dicha composicion para la